Financing Option. The Developers shall have the right, but not the obligation, to invest in any equity or debt financing related to the Monterde Project in percentage amounts equal to their respective percentage interest in the outstanding shares of KRI acquired pursuant to Section 3.03 above. Provided, however, that the Developers' resulting interests and those of Affiliates or parties with whom they have a voting agreement for the voting of KRI shares do not collectively exceed 25% of the then outstanding shares of KRI. KRI will give the Developers notice of its intention to carry out a financing and the Developers shall have ten (10) business days in which to declare their intentions to KRI.
Financing Option. If Customer elects to lease the pertinent Products and/or Services, Customer:
Financing Option. Prior to the closing of the merger, Purchaser shall have until September 29, 2000 to purchase up to $5,000,000 of the Seller's common stock at $.20 per share."
Financing Option. Entry into this financing arrangement is not a condition of obtaining insurance. You may opt to pay the premium for such insurance without financing such premium, or to obtain financing from some other source if you choose. State: NY PREMIUM ASSIGNMENT C O R P O R A T I O N (logo) ----SCHEDULED POLICIES OF INSURANCE V8(0)N13.69 BALTIA AIRLINES INC XXX XXXX XXXXXXX XXXX 000 XXXX000 XXXXXXX, XX 00000 (000) 000-0000 ***C752093*** AVIATION RJSK MGMT ASSOCIATES INC 19766 000 X XXXXXXXX XX XXXXXXX XXXX, XX 00000-0000 (000) 000-0000 Premium Down Payment Unpaid Balance Doc Stamps/Fees Amt. Financed Finance Charges Total Payments 162,300.00 40,575.00 (25%) 121,725.00 0.00 121,725.00 2,056.90 123,781.90 Payment Payments Rate First Due Type Status Contract Type 12,378.19 10 3.67% 2/8/2013 INVOICE NEW COMMERCIAL EFF DATE EXP DATE COMPANY /BROKER CITY ST CO. # TYPE MEP POLICY NO. TOTAL PREMIUM 1/8/2013 1/8/2014 CO: STAR INS CO MGA: XXXXXXXXXX XX 00000 AIR 0.00% AC076384 401 134,800.00 1/8/2013 1/8/2014 CO: LLOYDS OF LONDON MGA: AVIATION RISK MGMT ASSOC TALLAHASSEE CRYSTAL LAK FL TL 82864 67075 EXCS 0.00% AVNPE12 00089 27,500.00 Created By: __UFNM36______________________________________ Auth Code: ________________________________ ADDITIONAL REPRESENTATIONS & WARRANTIES OF PRODUCER
Financing Option. Vendor understands and agrees that, at Exelon’s option, some or all of the Equipment may be financed or leased through a third-party (hereinafter the “Third-Party Lessor”). Vendor agrees to sell the Equipment to any such Third-Party Lessor as Exelon may in writing direct upon the same or equivalent terms and conditions as set forth herein with respect to the sale to Exelon. Vendor shall execute and deliver any documents necessary to effect such financing or leasing transaction. Any representations made by Vendor or warranties extended by Vendor herein shall continue to run to Exelon and be enforceable by Exelon irrespective of Exelon’s entering into a financing or leasing transaction involving transfer of title or direct purchase by Third-Party Lessor.
Financing Option. At its option, subject to Section 1.01(f), Greenbrook may finance the purchase of any New System with a down payment of [***] and the balance paid in equal installments over thirty-six (36) monthly payments (each a “Monthly Payment”), which Monthly Payment Greenbrook will pay for each New System on the first day of each calendar month beginning on the first day of the first calendar month that is at least thirty (30) days after the date of shipment, whether or not Neuronetics invoices Greenbrook for such payments.
Financing Option. Confidential material redacted and filed separately with the Commission.
Financing Option. If ViaCyte has not consummated a bona fide preferred stock financing (in either a single transaction or a series of related transactions) by January 15, 2019 resulting in ViaCyte receiving (or providing that ViaCyte will receive) at least $25 million in total proceeds (excluding the conversion of any convertible notes), then ViaCyte shall have the option, which it may exercise, in its sole discretion, at any time after January 15, 2019 and prior to February 1, 2019, to obtain $10,000,000 in financing from CRISPR through ViaCyte’s issuance of a convertible promissory note (the “Convertible Note Financing”) by giving written notice (the “Financing Notice”) to CRISPR, indicating the decision to proceed with the Convertible Note Financing and providing drafts of (i) a convertible note purchase agreement for the Convertible Note Financing containing customary representations, warranties and covenants and (ii) a convertible promissory note containing customary terms such as interest rate and maturity date (the documents described in clauses (i) and (ii), together with any document, agreement or instrument contemplated thereby or referenced therein, are collectively referred to as the “Convertible Note Financing Documents”). The Parties acknowledge and agree that the material terms and conditions of the Convertible Note Financing Documents will be consistent with the terms and conditions of the convertible note financing consummated by ViaCyte and attached hereto, with redactions, as Exhibit E. Upon receipt of the Financing Notice and the draft Convertible Note Financing Documents, ViaCyte and CRISPR shall negotiate in good faith the terms and conditions of the Convertible Note Financing Documents. The Parties acknowledge and agree that the (x) Parties intend that the convertible note issued in connection with the Convertible Note Financing will convert at the same price and other terms and conditions as other investors in connection with the first bona fide equity financing of ViaCyte that occurs after the Effective Date in which the total proceeds thereof is not less than $25 million (excluding the conversion of such convertible note) (in either a single transaction or series of related transactions, a “Qualified Financing”) and provided that if the Qualified Financing is to take place over multiple tranches, that the conversion of the note will similarly occur in pro rata portions at the closing of each tranche; and (y) rights and obligations set forth in this...
Financing Option. 10.1 Within 75 days of receiving a Production Notice, Rimfire may request that Evanachan arrange project financing required for Mine Costs (the “Financing Option”), in return for an additional undivided 5% legal and beneficial Interest in the Property on the terms and conditions described in this Section 10.0.
Financing Option. 7.2.1 Provided that Evanachan has exercised the Second Option, and the joint venture has not yet been formed pursuant to Section 7.1, within 75 days of receiving a Production Notice (as defined in the joint venture agreement attached as Schedule B), Rimfire may request that Evanachan arrange project financing required for mine costs (the “Financing Option”), in return for an additional undivided 5% legal and beneficial interest in the Property on the terms and conditions described in this Section 7.2.
